Quote | Calliditas Therapeutics AB - Class B (OTCMKTS:CLTEF)
Last: | $7.55 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $7.55 |
High: | $0 |
Low: | $0 |
Volume: | 1 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Calliditas Therapeutics AB - Class B (OTCMKTS:CLTEF)
2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...
2024-05-28 10:20:20 ET Summary Asahi Kasei will acquire Calliditas Therapeutics AB (publ) for $1.1 billion, representing an 83% premium to the closing price on the Stockholm exchange and a 74% premium to the Nasdaq closing price. The primary asset of interest in the acquisition is...
Message Board Posts | Calliditas Therapeutics AB - Class B (OTCMKTS:CLTEF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB - Class B Company Name:
CLTEF Stock Symbol:
OTCMKTS Market:
Calliditas Therapeutics AB - Class B Website:
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...